Morgan Stanley raised the firm’s price target on Arcellx (ACLX) to $106 from $81 and keeps an Overweight rating on the shares. The firm is increasing its view of the odds of success for anito-cel following the initial data set from Arcellx’s iMMagine-1 Phase 2 trial in relapsed/refractory multiple myeloma patients, or rrMM. The firm sees “ample market share opportunity” for anito-cel, initially in later-line patients and eventually in earlier-line patients, should the current clinical profile largely hold, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACLX:
- Arcellx price target raised to $100 from $84 at BofA
- Arcellx price target raised to $95 from $80 at H.C. Wainwright
- Arcellx management to meet virtually with Piper Sandler
- Arcellx to present data for Its Phase 1and iMMagine-1studies to treat RRMM
- Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
